Containing Bifidobacterium lactis HN019™, HOWARU^® Transit (Bifido) is proven to reduce colonic transit time and relieve digestive discomfort.

In 2011, a two-week, triple-blind, randomized, placebo-controlled trial was conducted, in which 100 healthy volunteers were randomized into 3 groups during 14 days of treatment with a wash-out period of 7 days: Group 1 – probiotics of high dose (1.72X10¹⁰ CFU per day), Group 2 – probiotics of lose dose (1.8X10⁹ CFU per day), or Group 3 – placebo. The study was to assess the impact of Bifidobacterium lactis HN019™ on colonic transit times at different doses. The study was published on Scandinavian Journal of Gastroenterology.

Data show that the high-dose group saw colonic transit time reduced by 28 hours, compared to 18 hours for the low-dose group and no substantial improvement in placebo group. In the meantime, Bifidobacterium lactis HN019™ at high or low doses significantly modulated gut microflora and eased digestive discomfort.

HOWARU^® Transit (Bifidobacterium lactis HN019™) received a health claim approved by Switzerland, Canada, Japan and Brazil for its benefits to gastrointestinal health. IFF has hence become the first food and dietary supplement manufacturer to receive a probiotics health claim in a European country.

Colonic transit time is the amount of time it takes ingested food to travel through the human gut. An increase in colonic transiting time indicates the presence of digestive symptoms such as constipation.